Form 4: Intellia Therapeutics CEO John Leonard Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Intellia Therapeutics CEO John Leonard sold shares to cover tax obligations related to vesting RSUs, while also reporting shares held indirectly through a trust.
Summary
- On January 3, 2025, John M. Leonard, the President and CEO of Intellia Therapeutics, Inc., sold 26,807 shares of common stock at a price of $12.18 per share.
- This transaction was a mandatory 'sell-to-cover' to satisfy tax withholding obligations upon the vesting of Restricted Stock Units (RSUs) on January 1, 2025.
- Following the transaction, Leonard directly owns 941,115 shares of Intellia Therapeutics common stock.
- Leonard also indirectly owns 58,415 shares through the John M. Leonard 2015 Irrevocable Trust.
Sentiment
Score: 5
Explanation: The document describes a routine transaction related to tax obligations, so the sentiment is neutral.
Industry Context
This is a routine transaction related to executive compensation and tax obligations. Sell-to-cover transactions are common when RSUs vest, and are not necessarily indicative of a negative outlook on the company.
Stakeholder Impact
- The sale of shares by the CEO could have a minor, temporary impact on the stock price, but is unlikely to have a significant long-term effect.
Key Dates
| Date | Description |
|---|---|
| 01/01/2025 | Vesting of Restricted Stock Units (RSUs) triggering tax obligations. |
| 01/03/2025 | Date of the stock sale transaction. |
| 01/07/2025 | Date of signature by attorney-in-fact. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.